Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 75 versus PREDNISONE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 75 versus PREDNISONE INTENSOL.
DEXONE 0.75 vs PREDNISONE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduce inflammation, immune response, and adrenal function.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
0.75 mg orally once daily, typically as part of a tapering regimen for anti-inflammatory or immunosuppressive effects.
5-60 mg orally once daily or divided twice daily, titrated to response.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours in adults with normal renal function; prolonged to 72-168 hours in severe renal impairment.
2-4 hours (terminal) for prednisone; prednisolone half-life 2-4 hours. Clinical context: shorter than anti-inflammatory effect due to delayed receptor-mediated action.
Renal: ~65-80% as unchanged drug; Fecal: ~10-15% as metabolites; Minor biliary excretion.
Renal: <30% unchanged; major metabolites (prednisolone, 20-dihydroprednisolone) conjugated and excreted in urine. Fecal: <10%.
Category C
Category D/X
Corticosteroid
Corticosteroid